Suppr超能文献

噻唑烷二酮衍生物作为抗氧化剂、α-淀粉酶抑制剂和抗糖尿病药物的发现潜力。

Discovery Potent of Thiazolidinedione Derivatives as Antioxidant, α-Amylase Inhibitor, and Antidiabetic Agent.

作者信息

Sameeh Manal Y, Khowdiary Manal M, Nassar Hisham S, Abdelall Mahmoud M, Alderhami Suliman A, Elhenawy Ahmed A

机构信息

Chemistry Department, Faculty of Applied Science, Alleeth University Collage, Umm Al-Qura University, Makkah 24211, Saudi Arabia.

Applied Surfactant Laboratory, Egyptian Petroleum Research Institute, Nasr City 11727, Cairo, Egypt.

出版信息

Biomedicines. 2021 Dec 23;10(1):24. doi: 10.3390/biomedicines10010024.

Abstract

This work aimed to synthesize safe antihyperglycemic derivatives bearing thiazolidinedione fragment based on spectral data. The DFT theory discussed the frontier molecular orbitals (FMOs), chemical reactivity of compounds, and molecular electrostatic potential (MEP) to explain interaction between thiazolidinediones and the biological receptor. α-amylase is known as the initiator-hydrolysis of the of polysaccharides; therefore, developing α-amylase inhibitors can open the way for a potential diabetes mellitus drug. The molecular docking simulation was performed into the active site of PPAR-γ and α-amylase. We evaluated in vitro α-amylase's potency and radical scavenging ability. The compound has the highest potency against α-amylase and radical scavenging compared to the reference drug and other members. They have been applied against anti-diabetic and anti-hyperlipidemic activity (in vivo) based on an alloxan-induced diabetic rat model during a 30-day treatment protocol. The most potent anti hyperglycemic members are and with reduction percentage of blood glucose level by 69.55% and 66.95%, respectively; compared with the normal control. Other members exhibited moderate to low anti-diabetic potency. All compounds showed a normal value against the tested biochemical parameters (CH, LDL, and HDL). The ADMET profile showed good oral bioavailability without any observed carcinogenesis effect.

摘要

本研究旨在基于光谱数据合成带有噻唑烷二酮片段的安全抗高血糖衍生物。密度泛函理论(DFT)探讨了前沿分子轨道(FMOs)、化合物的化学反应性以及分子静电势(MEP),以解释噻唑烷二酮与生物受体之间的相互作用。α-淀粉酶是多糖水解的起始酶;因此,开发α-淀粉酶抑制剂可为潜在的糖尿病药物开辟道路。进行了分子对接模拟,将其对接至PPAR-γ和α-淀粉酶的活性位点。我们评估了体外α-淀粉酶的活性和自由基清除能力。与参比药物和其他成员相比,该化合物对α-淀粉酶的活性和自由基清除能力最高。在为期30天的治疗方案中,基于四氧嘧啶诱导的糖尿病大鼠模型,它们已被用于抗糖尿病和抗高血脂活性(体内)研究。最有效的抗高血糖成员是[具体化合物1]和[具体化合物2],血糖水平降低百分比分别为69.55%和66.95%;与正常对照组相比。其他成员表现出中度至低度的抗糖尿病活性。所有化合物对所测试的生化参数(CH、LDL和HDL)均显示正常数值。ADMET分析表明其具有良好的口服生物利用度,未观察到任何致癌作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/612c/8773338/ffa594b51df0/biomedicines-10-00024-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验